MaiFantuo® is the commercial brand name of Mavacamten, a first-in-class, allosteric and reversible cardiac myosin inhibitor developed by Bristol Myers Squibb. It works by reducing excessive actin-myosin cross-bridge formation, thereby decreasing hypercontractility of the heart muscle and improving left ventricular…
Evrenzo® is the commercial brand name of Roxadustat, an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). It stabilizes hypoxia-inducible factor (HIF), thereby stimulating endogenous erythropoietin production and improving iron utilization to treat anemia. Main Indications Treatment of anemia associated…
Linzess® is the commercial brand name of Linaclotide, an orally administered guanylate cyclase-C (GC-C) agonist developed by Ironwood Pharmaceuticals and marketed by AstraZeneca in China. It acts locally on the intestinal epithelium to increase intestinal fluid secretion and accelerate transit,…
Cerezyme® (generic name: imiglucerase) is an enzyme replacement therapy (ERT) developed by Sanofi Genzyme for Gaucher disease. It is a recombinant DNA-derived analog of human β-glucocerebrosidase, which catalyzes the hydrolysis of accumulated glucocerebroside into glucose and ceramide to reduce toxic…
Dorner® is the commercial brand name of Beraprost sodium, an orally active prostacyclin (PGI2) analogue developed by Toray Industries of Japan. It acts on prostacyclin receptors on blood vessels and platelets to dilate blood vessels and inhibit platelet aggregation, thus…